Home

About Us

Research

The Team

In the News

Contact Us

Absynth in the news

The following articles have showcased Absynth Biologics (please note that we are not responsible for the content of external websites).

1. BBSRC Leaflet. Jan 2008. Issue: Tackling ‘Superbugs’
New companies take up the fight. Absynth Biologics.
p. 14. “… a unique group of surface-exposed proteins of S. aureus … are good novel targets for a vaccine and for prophylactic or therapeutic antibodies control of infection … The research findings are being taken towards clinical application by ABsynth Biologics.”

Get a copy at: http://www.bbsrc.ac.uk/publications/corporate/bioscience_behind_superbugs.pdf

General enquiries or comments about the material included in this leaflet contact: external.relations@bbsrc.ac.uk

2. BBSRC business. Jul 2007. Spin out sets to tackle MRSA.
p. 12. “Through underpinning BBSRC-funded research we have identified a unique pool of immunological targets, with esential roles in cellular physiology and pathogenicity … Absynth Biologics gives an exciting opportunity to translate our basic research into real clinical application”

Get a copy at: http://www.bbsrc.ac.uk

3. Helix - Bioscience cluster news from Yorkshire Forward. May 2007.
Issue 07. ABsynth Biologics: Spin out company battles superbug.
p. 2. “The concept (Absynth Biologics) uses an immunological approach to target a novel set of proteins ... important for the growth and/or pathogenesis of the bacterium …”

Enquiries to Dr Danielle Hankin – Yorkshire Forward Bioscience Cluster manager.
  danielle.hankin@yorkshire-forward.com.
  www.bioscience-yorkshire.com

4. BBSRC Follow-On Funding. Jan 2007. Case study: Spin out set to tackle MRSA (“Absynth”).
http://bbsrc.mondosearch.com

 

 

Site Map